Trial Profile
A double-blind, placebo-controlled multicentre trial of memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Feb 2023
Price :
$35
*
At a glance
- Drugs Memantine (Primary)
- Indications Dementia; Lewy body disease; Parkinson's disease
- Focus Therapeutic Use
- Acronyms MEMPDD
- 09 Feb 2023 This trial has been completed in Sweden, according to European Clinical Trials Database record. (1 Feb 2008)
- 25 Apr 2015 Pooled analysis results of this trial and other two 24-Week , placebo-controlled trials presented at the 67th Annual Meeting of the American Academy of Neurology.
- 17 Jul 2013 Secondary endpoint (Clinical Dementia Rating) results presented at the 2013 Alzheimer's Association International Conference .